Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;27(3):287-290.
doi: 10.1111/tbj.14170. Epub 2021 Jan 27.

Atypical ductal hyperplasia on core needle biopsy: Surgical outcomes of 200 consecutive cases from a high-volume breast program

Pawel Karwowski  1 , Dean Lumley  2 , Deidre Stokes  2 , Matthew Pavlica  2 , Bonnie Edsall  1   3 , Sophia Fu  4 , John Francfort  4 , Bradley Cohen  4 , Anthony Capizzi  4 , Zhi-Wei Ma  5 , Anne Green  3 , Johnny Kao  1
Affiliations

Atypical ductal hyperplasia on core needle biopsy: Surgical outcomes of 200 consecutive cases from a high-volume breast program

Pawel Karwowski et al. Breast J. 2021 Mar.

Abstract

Atypical ductal hyperplasia (ADH) is an indication for excisional biopsy to rule out occult breast cancer. We analyzed pathological findings on excisional biopsy for ADH diagnosed in a high volume breast center equipped with digital tomosynthesis. Two hundred consecutive patients were diagnosed with ADH on core biopsy with radiographic concordance followed by excisional biopsy. On excisional biopsy, 33 patients (16.5%) were diagnosed with DCIS or invasive breast cancer. Patients with a concurrent diagnosis of papilloma had a higher risk of upstaging on both univariate and multivariate analysis (41.7% vs. 14.9%, p=0.015). No other statistically significant predictors of upgrading were identified (p>0.05).

Keywords: atypical ductal hyperplasia; core needle biopsy; digital tomosynthesis; upgrading.

PubMed Disclaimer

References

REFERENCES

    1. East EG, Carter CS, Kleer CG. Atypical ductal lesions of the breast: criteria, significance, and laboratory updates. Arch Pathol Lab Med. 2018;142:1182-1185.
    1. Mooney KL, Bassett LW, Apple SK. Upstage rates of high-risk breast lesions diagnosed on core needle biopsy: a single-institution experience and literature review. Mod Pathol. 2016;29:1471-1484.
    1. Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL. Subsequent breast cancer risk following diagnosis of atypical ductal hyperplasia on needle biopsy. JAMA Oncol. 2017;3:36-41.
    1. Schiaffino S, Calabrese M, Melani EF, et al. Upstage Rate of percutaneously diagnosed pure atypical ductal hyperplasia: systematic review and meta-analysis of 6458 lesions. Radiology. 2020;294:76-86.
    1. Bahl M, Barzilay R, Yedidia AB, Locascio NJ, Yu L, Lehman CD. High-risk breast lesions: a machine learning model to predict pathologic upstage and reduce unnecessary surgical excision. Radiology. 2018;286:810-818.

Publication types

MeSH terms

LinkOut - more resources